Literature DB >> 22966403

Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma.

Peng Zhang1, Yi-Ping Han, Ling Huang, Qiang Li, DA-Lie Ma.   

Abstract

Napsin A is a newly discovered functional aspartic proteinase that is expressed in normal lung parenchyma in type II pneumocytes and is thought to be associated with primary lung adenocarcinoma. Thyroid transcription factor-1 (TTF-1) is a widely used relatively restricted marker for lung adenocarcinoma. The present study aimed to compare the usefulness of napsin A with TTF-1 for the identification of primary lung adenocarcinoma. Immunohistochemical expression of napsin A and TTF-1 was analyzed in 351 lung cancer tissues, including 27 metastases. Napsin A was expressed in 180 of 212 (84.9%) primary lung adenocarcinomas, while no expression was noted in all 27 metastatic lung cancer specimens, including 19 metastatic adenocarcinomas. In contrast, TTF-1 expression was not only noted in 179 of 212 (84.4%) primary lung adenocarcinomas, but also in 12 of 18 (66.7%) small-cell carcinomas and some of the squamous carcinomas, as well as in one metastatic adenocarcinoma from the thyroid. The sensitivity and specificity of napsin A for primary lung adenocarcinoma (84.9 and 93.8%, respectively) were higher than the sensitivity and specificity of TTF-1 (84.4 and 83.9%, respectively). By combining napsin A and TTF-1, sensitivity increased to 91.0%. Furthermore, the sensitivity and specificity expression was associated with gender, smoking history, performance status, pathological type, primary tumor size and nodal metastasis. Therefore, napsin A is a useful novel marker in the differential diagnosis of primary lung adenocarcinoma.

Entities:  

Year:  2010        PMID: 22966403      PMCID: PMC3436431          DOI: 10.3892/ol_00000160

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Napsins: new human aspartic proteinases. Distinction between two closely related genes.

Authors:  P J Tatnell; D J Powell; J Hill; T S Smith; D G Tew; J Kay
Journal:  FEBS Lett       Date:  1998-12-11       Impact factor: 4.124

2.  Human napsin A: expression, immunochemical detection, and tissue localization.

Authors:  V Schauer-Vukasinovic; D Bur; D Kling; F Grüninger; T Giller
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

3.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

Authors:  T Berghmans; M Paesmans; C Mascaux; B Martin; A-P Meert; A Haller; J-J Lafitte; J-P Sculier
Journal:  Ann Oncol       Date:  2006-09-15       Impact factor: 32.976

4.  Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1.

Authors:  M D Bruno; R J Bohinski; K M Huelsman; J A Whitsett; T R Korfhagen
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

5.  Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma.

Authors:  Takashi Hirano; Yunbo Gong; Koichi Yoshida; Yasufumi Kato; Koich Yashima; Masahiro Maeda; Ayako Nakagawa; Kaoru Fujioka; Tatsuo Ohira; Norihiko Ikeda; Yoshiro Ebihara; Gert Auer; Harubumi Kato
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

6.  Processing of pulmonary surfactant protein B by napsin and cathepsin H.

Authors:  Takayuki Ueno; Stig Linder; Cheng-Lun Na; Ward R Rice; Jan Johansson; Timothy E Weaver
Journal:  J Biol Chem       Date:  2004-02-06       Impact factor: 5.157

Review 7.  Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung.

Authors:  Jaishree Jagirdar
Journal:  Arch Pathol Lab Med       Date:  2008-03       Impact factor: 5.534

8.  Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A.

Authors:  T Hirano; G Auer; M Maeda; Y Hagiwara; S Okada; T Ohira; K Okuzawa; K Fujioka; B Franzén; N Hibi; T Seito; Y Ebihara; H Kato
Journal:  Jpn J Cancer Res       Date:  2000-10

9.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.

Authors:  T Ueno; S Linder; G Elmberger
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma.

Authors:  T Hirano; B Franzén; K Uryu; K Okuzawa; A A Alaiya; F Vanky; L Rodrigues; Y Ebihara; H Kato; G Auer
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  11 in total

1.  The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.

Authors:  Nehad M R Abd El-Maqsoud; Ehab Rifat Tawfiek; Ayman Abdelmeged; Mohamed Fathy Abdel Rahman; Alaa A E Moustafa
Journal:  Tumour Biol       Date:  2015-10-01

2.  Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.

Authors:  Yang Qu; Dan Zhao; Jing Mu; Nanying Che; Chen Zhang; Zichen Liu; Dan Su; Lijuan Zhou; Haiqing Zhang; Lixin Wei
Journal:  Tumour Biol       Date:  2015-08-09

3.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Authors:  Yoriko Yamashita; Tetsuro Nagasaka; Aya Naiki-Ito; Shinya Sato; Shugo Suzuki; Shinya Toyokuni; Masafumi Ito; Satoru Takahashi
Journal:  Mod Pathol       Date:  2014-04-11       Impact factor: 7.842

4.  Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.

Authors:  Jianghua Wu; Yanhui Zhang; Tingting Ding; Runfen Cheng; Wenchen Gong; Yuhong Guo; Ye Luo; Yi Pan; Qiongli Zhai; Wei Sun; Dongmei Lin; Baocun Sun
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

5.  Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Authors:  Grzegorz T Gurda; Lei Zhang; Yuting Wang; Li Chen; Susan Geddes; William C Cho; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Clin Transl Med       Date:  2015-04-21

6.  The high diagnostic accuracy of combined test of thyroid transcription factor 1 and Napsin A to distinguish between lung adenocarcinoma and squamous cell carcinoma: a meta-analysis.

Authors:  Li Li; Xiaorong Li; Jieyun Yin; Xia Song; Xiaochen Chen; Jiane Feng; Hongyu Gao; Li Liu; Sheng Wei
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

7.  Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma.

Authors:  Xiao-Nan Wang; Shu-Jing Wang; Vijay Pandey; Ping Chen; Qing Li; Zheng-Sheng Wu; Qiang Wu; Peter E Lobie
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

8.  The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.

Authors:  Marina Piljić Burazer; Suzana Mladinov; Vesna Ćapkun; Sendi Kuret; Merica Glavina Durdov
Journal:  Med Sci Monit       Date:  2017-01-27

Review 9.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

10.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.